Figure 2

Human LAK cell sensitivity of MDA-MB-231 breast carcinoma cell lines expressed as LU. Using the same experimental design as in Fig. 1, results obtained from LAK CML experiments with MDA-MB-231 breast carcinoma cell lines are demonstrated as lytic units ± standard deviation. 1 = MDA-MB-231 (drug-sensitive breast carcinoma cell line), 2 = MPAM-26 (murine P-gp transfected variant of MDA-MB-231), 3 = MPAHS-1-10 (human P-gp transfected variant of MDA-MB-231), 4 = MPAHS-1-300 (human P-gp transfected variant of MDA-MB-231),5 = MPAHS-DOX150 (human P-gp transfected variant of MDA-MB-231). The results shown are from an experiment representative of 15 independent experiments, performed by three independent investigators. LAK effectors were from three different donors. Results are expressed as LU/10⁶. Each lytic unit value is derived from 8 effector/target (E/T) ratios as described in the Methods.